Gustav Gaudernack

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.

Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.

Journal: Current opinion in oncology

Published: January 26, 2023

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

Journal: Journal of translational medicine

Published: August 10, 2022

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

Journal: Nature communications

Published: April 17, 2022

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.

Journal: Journal for immunotherapy of cancer

Published: April 14, 2022

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants.

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants.

Journal: HLA

Published: September 21, 2021

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.

Journal: Oncoimmunology

Published: July 08, 2021

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.

Journal: Frontiers in immunology

Published: March 18, 2021

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.

Journal: Frontiers in immunology

Published: February 03, 2021

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 16, 2020

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.

Journal: Frontiers in immunology

Published: June 12, 2020

Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.

Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.

Journal: Toxicology reports

Published: May 20, 2020

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.

Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: November 29, 2019

Showing 1-12 of 33

Last Updated: 09/26/2026